776 related articles for article (PubMed ID: 30251622)
1. Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial.
Holt RIG; Gossage-Worrall R; Hind D; Bradburn MJ; McCrone P; Morris T; Edwardson C; Barnard K; Carey ME; Davies MJ; Dickens CM; Doherty Y; Etherington A; French P; Gaughran F; Greenwood KE; Kalidindi S; Khunti K; Laugharne R; Pendlebury J; Rathod S; Saxon D; Shiers D; Siddiqi N; Swaby EA; Waller G; Wright S
Br J Psychiatry; 2019 Feb; 214(2):63-73. PubMed ID: 30251622
[TBL] [Abstract][Full Text] [Related]
2. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.
Hidalgo-Mazzei D; Berk M; Cipriani A; Cleare AJ; Florio AD; Dietch D; Geddes JR; Goodwin GM; Grunze H; Hayes JF; Jones I; Kasper S; Macritchie K; McAllister-Williams RH; Morriss R; Nayrouz S; Pappa S; Soares JC; Smith DJ; Suppes T; Talbot P; Vieta E; Watson S; Yatham LN; Young AH; Stokes PRA
Br J Psychiatry; 2019 Jan; 214(1):27-35. PubMed ID: 30520709
[TBL] [Abstract][Full Text] [Related]
3. Ketamine: stimulating antidepressant treatment?
Malhi GS; Byrow Y; Cassidy F; Cipriani A; Demyttenaere K; Frye MA; Gitlin M; Kennedy SH; Ketter TA; Lam RW; McShane R; Mitchell AJ; Ostacher MJ; Rizvi SJ; Thase ME; Tohen M
BJPsych Open; 2016 May; 2(3):e5-e9. PubMed ID: 27703782
[TBL] [Abstract][Full Text] [Related]
4. Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT.
Holt RI; Hind D; Gossage-Worrall R; Bradburn MJ; Saxon D; McCrone P; Morris TA; Etherington A; Shiers D; Barnard K; Swaby L; Edwardson C; Carey ME; Davies MJ; Dickens CM; Doherty Y; French P; Greenwood KE; Kalidindi S; Khunti K; Laugharne R; Pendlebury J; Rathod S; Siddiqi N; Wright S; Waller G; Gaughran F; Barnett J; Northern A
Health Technol Assess; 2018 Nov; 22(65):1-160. PubMed ID: 30499443
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
[No Abstract] [Full Text] [Related]
6. Early weight gain predicts later weight gain in depressed patients treated with antidepressants: Findings from the METADAP cohort.
Asmar KE; Fève B; Colle R; Gressier F; Vievard A; Trabado S; Verstuyft C; Haffen E; Polosan M; Ferreri F; Falissard B; Chanson P; Becquemont L; Corruble E
J Affect Disord; 2018 Dec; 241():22-28. PubMed ID: 30092445
[TBL] [Abstract][Full Text] [Related]
7. A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model.
McCormick D; Bhatt DL; Bays HE; Taub PR; Caldwell KA; Guerin CK; Steinhoff J; Ahmad Z; Singh R; Moreo K; Carter J; Heggen CL; Sapir T
J Manag Care Spec Pharm; 2020 Dec; 26(12):1517-1528. PubMed ID: 33251993
[No Abstract] [Full Text] [Related]
8. Multiple-therapy-resistant major depressive disorder: a clinically important concept.
McAllister-Williams RH; Christmas DMB; Cleare AJ; Currie A; Gledhill J; Insole L; Malizia AL; McGeever M; Morriss R; Robinson LJ; Scott M; Stokes PRA; Talbot PS; Young AH
Br J Psychiatry; 2018 May; 212(5):274-278. PubMed ID: 30517072
[TBL] [Abstract][Full Text] [Related]
9. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
J Urol; 2023 Jul; 210(1):224-226. PubMed ID: 37119051
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
Cannon AJ; Bargiota A; Billings L; Hunt B; Leiter LA; Malkin S; Mocarski M; Ranthe MF; Schiffman A; Doshi A
J Manag Care Spec Pharm; 2020 Feb; 26(2):143-153. PubMed ID: 31856636
[TBL] [Abstract][Full Text] [Related]
11. Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial.
Andersen E; Juhl CR; Kjøller ET; Lundgren JR; Janus C; Dehestani Y; Saupstad M; Ingerslev LR; Duun OM; Jensen SBK; Holst JJ; Stallknecht BM; Madsbad S; Torekov SS; Barrès R
Hum Reprod; 2022 Jun; 37(7):1414-1422. PubMed ID: 35580859
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples.
Fabbri C; Kasper S; Kautzky A; Bartova L; Dold M; Zohar J; Souery D; Montgomery S; Albani D; Raimondi I; Dikeos D; Rujescu D; Uher R; Lewis CM; Mendlewicz J; Serretti A
Br J Psychiatry; 2019 Jan; 214(1):36-41. PubMed ID: 30468137
[TBL] [Abstract][Full Text] [Related]
13. Annual costs among patients with major depressive disorder and the impact of key clinical events.
Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
[No Abstract] [Full Text] [Related]
14. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
Fendrick AM; Brixner D; Rubin DT; Mease P; Liu H; Davis M; Mittal M
J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
[No Abstract] [Full Text] [Related]
15. Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications.
Heile M; Wyne K; Billings LK; Cannon A; Handelsman Y; Shannon M
J Manag Care Spec Pharm; 2018 Sep; 24(9-a Suppl):S42-S52. PubMed ID: 30156446
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorder.
Kusumi I; Arai Y; Okubo R; Honda M; Matsuda Y; Matsuda Y; Tochigi A; Takekita Y; Yamanaka H; Uemura K; Ito K; Tsuchiya K; Yamada J; Yoshimura B; Mitsui N; Matsubara S; Segawa T; Nishi N; Sugawara Y; Kako Y; Shinkawa I; Shinohara K; Konishi A; Iga J; Hashimoto N; Inomata S; Tsukamoto N; Ito H; Ito YM; Sato N
BJPsych Open; 2018 Nov; 4(6):454-460. PubMed ID: 30450224
[TBL] [Abstract][Full Text] [Related]
17. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.
Newsome SD; Aliotta PJ; Bainbridge J; Bennett SE; Cutter G; Fenton K; Lublin F; Northrop D; Rintell D; Walker BD; Weigel M; Zackowski K; Jones DE
Int J MS Care; 2016; 18(6):314-323. PubMed ID: 27999526
[TBL] [Abstract][Full Text] [Related]
18. Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus.
Billings LK; Handelsman Y; Heile M; Schneider D; Wyne K
J Manag Care Spec Pharm; 2018 Sep; 24(9-a Suppl):S30-S41. PubMed ID: 30156447
[TBL] [Abstract][Full Text] [Related]
19. High heterogeneity and low reliability in the diagnosis of major depression will impair the development of new drugs.
Lieblich SM; Castle DJ; Pantelis C; Hopwood M; Young AH; Everall IP
BJPsych Open; 2015 Oct; 1(2):e5-e7. PubMed ID: 27703745
[TBL] [Abstract][Full Text] [Related]
20. Enhanced motivational interviewing for reducing weight and increasing physical activity in adults with high cardiovascular risk: the MOVE IT three-arm RCT.
Ismail K; Stahl D; Bayley A; Twist K; Stewart K; Ridge K; Britneff E; Ashworth M; de Zoysa N; Rundle J; Cook D; Whincup P; Treasure J; McCrone P; Greenough A; Winkley K
Health Technol Assess; 2019 Dec; 23(69):1-144. PubMed ID: 31858966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
